Oligoclonal selection of nanobodies targeting vascular endothelial growth factor

• Published in: Journal of immunotoxicology Vol. 16; no. 1; pp. 34 - 42
• Main Authors: Ahadi, Mehrdad, Ghasemian, Haniyeh, Behdani, Mahdi, Kazemi-Lomedasht, Fatemeh
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.01.2019; Taylor & Francis Group
• Subjects: angiogenesis; Animals; Antibodies, Monoclonal - chemistry; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacology; Camelus - immunology; Cell Proliferation - drug effects; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells - cytology; Human Umbilical Vein Endothelial Cells - immunology; Humans; Oligoclonal nanobody; Single-Domain Antibodies - chemistry; Single-Domain Antibodies - immunology; Single-Domain Antibodies - pharmacology; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular Endothelial Growth Factor A - immunology; VEGF; Oligoclonal nanobody; VEGF; angiogenesis

While monoclonal antibodies are efficient therapeutics for cancer treatment, nanobodies or variable heavy domain - due to their small size, high stability, and solubility - have many advantages in comparison. Oligoclonal nanobodies are a mixture of nanobodies against different epitopes of an antigen...